0.83
4.40%
0.035
Handel nachbörslich:
.80
-0.03
-3.61%
Painreform Ltd Aktie (PRFX) Neueste Nachrichten
Navigating PRFX’s Stock Market Maze: Ups and Downs in 2023 - The InvestChronicle
Financial Health Check: Examining PainReform Ltd (PRFX)’s Key Ratios - The Dwinnex
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.23% - MSN
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.23% - MSN
United States shares mixed at close of trade; Dow Jones Industrial Average down 0.23% - MSN
PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110 - GlobeNewswire
PainReform Ltd. Launches Warrant Exercise Incentive Program - TipRanks
PainReform confirms sutures compatibility for in trial for PRF-110 - TipRanks
PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110 - StockTitan
Ratio Analysis: Unpacking PainReform Ltd (PRFX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
PainReform to issue new warrants in stock exercise deal By Investing.com - Investing.com Australia
PainReform Shares Are Trading Lower Today: What's Going On - Benzinga
PRFX stock touches 52-week low at $1.17 amid steep annual decline - Investing.com
PRFX stock touches 52-week low at $1.17 amid steep annual decline - Investing.com UK
PainReform to issue new warrants in stock exercise deal - Investing.com
PainReform to issue new warrants in stock exercise deal By Investing.com - Investing.com Canada
PainReform to issue new warrants in stock exercise deal By Investing.com - Investing.com UK
PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds - GlobeNewswire
PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds - StockTitan
Holdings of PainReform Ltd (PRFX) are aligned with the stars - SETE News
PainReform Ltd [PRFX] is -90.64% lower this YTD. Is it still time to buy? - The DBT News
Upcoming Stock Splits This Week (September 9 to September 13) – Stay InvestingTHE BHARAT EXPRESS NEWS - The Bharat Express News
PainReform Ltd: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - The InvestChronicle
PainReform Ltd (PRFX) stock analysis: A simple moving average approach - US Post News
PainReform Ltd’s Mixed Bag: Down -90.20% in 6 Months, Down -38.34% in 30 Days - The InvestChronicle
PainReform Announces Reverse Share Split - TipRanks
Market Momentum: PainReform Ltd (PRFX) Registers a -4.21 Decrease, Closing at 0.22 - The Dwinnex
PainReform (NASDAQ:PRFX) Shares Down 11.7% - Defense World
PRFX stock touches 52-week low at $0.24 amid sharp annual decline - Investing.com
Market Insight: PainReform Ltd (PRFX)’s Notable Gain, Closing at 0.27 - The Dwinnex
The time has not yet come to remove your chips from the table: PainReform Ltd (PRFX) - SETE News
PainReform Ltd. Schedules 2024 Annual Meeting - TipRanks
Do investors need to be concerned about PainReform Ltd (PRFX)? - US Post News
Prepare Yourself for Liftoff: PainReform Ltd (PRFX) - SETE News
PainReform reports breakthrough in post-surgical pain management - Investing.com India
PainReform reports breakthrough in post-surgical pain management - Investing.com
PainReform Bunionectomy Study Observations Confirm Optimal Delivery Method for PRF-110 in Bunionectomy Procedures - Yahoo Finance
PainReform Bunionectomy Study Observations Confirm Optimal - GlobeNewswire
Ratios Reveal: Breaking Down PainReform Ltd (PRFX)’s Financial Health - The Dwinnex
PainReform reports safety data from Phase III bunionectomy trial of PRF-110 - Yahoo Finance
PRFX stock touches 52-week low at $0.28 amid sharp annual decline - Investing.com India
PainReform reports positive early safety data in Phase 3 study - Investing.com India
PainReform Ltd: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
PainReform reports positive early safety data in Phase 3 study - Investing.com
PRFX stock touches 52-week low at $0.28 amid sharp annual decline - Investing.com
PRFX stock touches 52-week low at $0.28 amid sharp annual decline - Investing.com Canada
PRFX stock touches 52-week low at $0.28 amid sharp annual decline - Investing.com Australia
PRFX stock touches 52-week low at $0.28 amid sharp annual decline - Investing.com UK
PRFX Stock Earnings: PainReform Beats EPS for Q2 2024 - MSN
PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study - GlobeNewswire
PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study - StockTitan
PainReform announces safety profile for PRF-110 in Phase 3 study - TipRanks
PRFX (PainReform) Cyclically Adjusted Book per Share : $0.00 (As of Mar. 2024) - GuruFocus.com
PainReform Reports Significant Asset Decline - TipRanks
PainReform Provides Business Update for the Second Quarter of 2024 - GlobeNewswire
PainReform Provides Business Update for the Second Quarter of 2024 - StockTitan
PainReform Provides Business Update for the Second Quarter of 2024 - Yahoo Finance
PainReform Shareholders Approve Key Proposals - TipRanks
PainReform develops new postoperative pain relief therapy - Investing.com
PainReform Announces Development and Successful - GlobeNewswire
PainReform Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic Effects - Yahoo Finance
PainReform Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic Effects - StockTitan
Balance Sheet Breakdown: PainReform Ltd (PRFX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
PainReform reports positive safety data for PRF-110 By Investing.com - Investing.com Canada
PainReform reports positive safety data for PRF-110 - Investing.com India
PainReform reports positive safety data for PRF-110 - Investing.com
PainReform Announces Favorable Safety Profile of PRF-110, - GlobeNewswire
PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses - StockTitan
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):